Delivery Order SPE2DB22D3004-SPE2DB25FSH00
Award Date 9/4/25
Potential Completion Date 9/5/25
Potential Value $2.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $5,303.54 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. HEPLISAV-B is a recombinant zoster vaccine indicated for the prevention of herpes zoster in adults aged 50 years and older, representing part of the federal government's medical supply requirements for military...
- The Defense Logistics Agency awarded a $157,217.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with a completion date of July 30, 2025. HEPLISAV-B is a recombinant zoster vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 and older. This delivery order represents a non-set-aside, competitively awarded contract utilizing AmerisourceBergen's existing indefinite delivery vehicle with the DLA. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $9,743.10 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 4, 2025, with completion scheduled for September 5, 2025. This non-set-aside, firm fixed-price delivery order represents a single pharmaceutical procurement supporting federal medical supply needs. The award was made through competitive procurement processes to the prime contractor, whose corporate office is located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on July 31, 2025, with completion scheduled for August 1, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine used for immunization of adults. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and is being performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B virus infection in adults 18...
- The Defense Logistics Agency awarded a delivery order valued at $2,106.20 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older, and this...
- The Defense Logistics Agency awarded a delivery order valued at $4,890.36 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 29, 2025, with completion targeted for September 2, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order for the hepatitis B vaccine product, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award is issued as a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $3,369.92 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on August 13, 2025, with an ultimate completion date of August 14, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 years and older. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...